234 related articles for article (PubMed ID: 25860621)
1. Prediction of Drug-Induced Liver Injury in HepG2 Cells Cultured with Human Liver Microsomes.
Choi JM; Oh SJ; Lee JY; Jeon JS; Ryu CS; Kim YM; Lee K; Kim SK
Chem Res Toxicol; 2015 May; 28(5):872-85. PubMed ID: 25860621
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
3. Metabolic activation of hepatotoxic drug (benzbromarone) induced mitochondrial membrane permeability transition.
Shirakawa M; Sekine S; Tanaka A; Horie T; Ito K
Toxicol Appl Pharmacol; 2015 Oct; 288(1):12-8. PubMed ID: 26148448
[TBL] [Abstract][Full Text] [Related]
4. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
5. Investigation of CYP2B6, 3A4 and β-esterase interactions of Withania somnifera (L.) dunal in human liver microsomes and HepG2 cells.
Kumar S; Bouic PJ; Rosenkranz B
J Ethnopharmacol; 2021 Apr; 270():113766. PubMed ID: 33395575
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins.
Usui T; Mise M; Hashizume T; Yabuki M; Komuro S
Drug Metab Dispos; 2009 Dec; 37(12):2383-92. PubMed ID: 19720731
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
Baldwin A; Huang Z; Jounaidi Y; Waxman DJ
Arch Biochem Biophys; 2003 Jan; 409(1):197-206. PubMed ID: 12464259
[TBL] [Abstract][Full Text] [Related]
8. Role of cytochrome P450 and UDP-glucuronosyltransferases in metabolic pathway of homoegonol in human liver microsomes.
Kwon SS; Kim JH; Jeong HU; Ahn KS; Oh SR; Lee HS
Drug Metab Pharmacokinet; 2015 Aug; 30(4):305-13. PubMed ID: 26163112
[TBL] [Abstract][Full Text] [Related]
9. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Chang TK; Weber GF; Crespi CL; Waxman DJ
Cancer Res; 1993 Dec; 53(23):5629-37. PubMed ID: 8242617
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
11. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.
Xuan J; Chen S; Ning B; Tolleson WH; Guo L
Chem Biol Interact; 2016 Aug; 255():63-73. PubMed ID: 26477383
[TBL] [Abstract][Full Text] [Related]
12. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.
Gómez-Lechón MJ; Tolosa L; Donato MT
J Appl Toxicol; 2016 Jun; 36(6):752-68. PubMed ID: 26691983
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
14. NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition.
Kosaka M; Zhang D; Wong S; Yan Z
Drug Metab Dispos; 2020 Aug; 48(8):655-661. PubMed ID: 32482757
[TBL] [Abstract][Full Text] [Related]
15. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
16. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
Huskey SW; Dean DC; Miller RR; Rasmusson GH; Chiu SH
Drug Metab Dispos; 1995 Oct; 23(10):1126-35. PubMed ID: 8654202
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Metabolism of Sakuranetin and Its Modulating Effects on Cytochrome P450s and UDP-Glucuronosyltransferases.
Jeong H; Lee J; Kim S; Yeo YY; So H; Wu H; Song YS; Jang CY; Kim HD; Kim MJ; Chang M
Molecules; 2018 Jun; 23(7):. PubMed ID: 29949932
[TBL] [Abstract][Full Text] [Related]
18. Human cytochrome P450 isozymes in metabolism and health effects of gasoline ethers.
Hong JY; Wang YY; Mohr SN; Bondoc FY; Deng C
Res Rep Health Eff Inst; 2001 May; (102):7-27; discussion 95-109. PubMed ID: 11504148
[TBL] [Abstract][Full Text] [Related]
19. Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats.
Zhai J; Zhang F; Gao S; Chen L; Feng G; Yin J; Chen W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28786954
[TBL] [Abstract][Full Text] [Related]
20. Metabolic-induced cytotoxicity of diosbulbin B in CYP3A4-expressing cells.
Jiang JZ; Yang BH; Ji LL; Yang L; Mao YC; Hu ZH; Wang ZT; Wang CH
Toxicol In Vitro; 2017 Feb; 38():59-66. PubMed ID: 27836570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
